Warning Letter — Ohom Padmaavathii, LLC
The FDA issued a Warning Letter to Ohom Padmaavathii, LLC following an evaluation by the Office of Inspections and Investigations.
Ohom Padmaavathii, LLC and its operational departments including quality assurance, manufacturing, and regulatory compliance.
The issuance of a Warning Letter indicates that the FDA identified significant violations of regulatory requirements during an inspection or investigation. For regulatory professionals, this represents an escalation of enforcement action that requires formal remediation to avoid further consequences, such as seizure or injunction. The involvement of the Office of Inspections and Investigations suggests specific compliance deficiencies in the firm's operations.
Review facility inspection readiness and ensure all manufacturing and distribution processes align with established quality system requirements. Regulatory teams should assess current compliance documentation for potential gaps that may trigger Office of Inspections and Investigations scrutiny.
FDA Warning Letter issued to: Ohom Padmaavathii, LLC. 07/22/2026 — Office of Inspections and Investigations. Source: https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/ohom-padmaavathii-llc-723534-07222026
Open in openFDA / FDA.gov